Norway to Ban Sale of Menthol and Capsule Cigarettes by 2024

Regulations by 2FIRSTS.ai
Nov.23.2023
Norway to Ban Sale of Menthol and Capsule Cigarettes by 2024
Norway will ban the sale of menthol cigarettes, capsule cigarettes, and flavored e-cigarettes by 2024, making it the last European country to do so.

According to a report from the Norwegian news website bt.no, Norway is set to ban the sale of menthol cigarettes and flavored tobacco products called "bursting beads" by 2024, making it the last country in Europe to prohibit these types of products. Additionally, Norway will also prohibit the sale of flavored e-cigarettes.

 

Norway is one of the few countries in Europe that still allows the sale of menthol cigarettes and cigarettes with "burst beads". However, starting next year, this situation will change completely as the tobacco market in Norway will no longer offer flavored cigarettes or cigarettes with burst beads. The ban on flavors means that only e-cigarettes or supplements with a tobacco flavor will be available for sale in the market.

 

In fact, the ban on menthol cigarettes in Norway has been a long time coming. As part of the European Union Tobacco Products Directive (TPD), the Norwegian government had previously indicated its intention to implement this regulation in 2021. However, due to encountering some obstacles within the EU and other countries, the plan has been forced to be postponed.

 

The Norwegian Ministry of Health and Social Services is projecting that this ban will come into effect in 2024, although the exact date has not been confirmed.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13
France Vape Market 2026: Use Reaches 7.9% Amid Tax, Regulatory and Scientific Debate
France Vape Market 2026: Use Reaches 7.9% Amid Tax, Regulatory and Scientific Debate
France remains one of Europe’s active vape markets in 2026, with adult vaping prevalence rising to 7.9%; at the same time, e-liquid taxation, public-space restrictions, advertising compliance and health-risk debate are pushing the industry into a critical policy period.
Jun.23
Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
As the European Commission reviews its tobacco and advertising rules, two experts who provided written comments to 2Firsts argue that future EU policy should not overlook adult smokers’ alternatives. Dr Garrett McGovern and Dr Carmen Escrig say regulators should weigh relative risk, adult switching, flavours, consumer behaviour and scientific uncertainty alongside youth protection.
Industry Insight
Jun.01
One Year After UK Disposable Vape Ban: Youth Use Falls to 13%, Adult Use to 8%
One Year After UK Disposable Vape Ban: Youth Use Falls to 13%, Adult Use to 8%
among both youth and adults. However, industry groups and regulators warn that the illicit vape market remains a growing concern.
Jun.09
Thailand’s DDC Reaffirms Nicotine Pouches Are Regulated Under the Tobacco Products Control Act
Thailand’s DDC Reaffirms Nicotine Pouches Are Regulated Under the Tobacco Products Control Act
Thailand’s Department of Disease Control has warned the public not to believe claims that nicotine pouches are harmless, saying the products contain high levels of nicotine that can enter the bloodstream through the mouth lining and affect the nervous system and brain.
Apr.30 by 2FIRSTS.ai
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Vapesourcing has listed RELX Creator Pro 15K as “Coming Soon” with U.S. warehouse shipping options; while the page does not show that RELX has entered the U.S. market through official channels or that the product has received FDA authorization, the listing suggests that Chinese brand-led ENDS products are becoming a new point of observation as the U.S. market reassesses regulatory risk following the FDA’s updated enforcement-priority policy.
Industry Insight
Jun.11